Treating postpartum depression with brexanolone.

Jessica Burval, Rachel Kerns, Kim Reed

Nursing 2020 May

filter terms:

all
compound
phenotype
show more »
show less «

The FDA has approved brexanolone specifically for treatment of adults with postpartum depression (PPD). Administered I.V., it can relieve severe signs and symptoms of PPD within days rather than weeks. This article discusses the benefits and risks of brexanolone as a treatment for PPD, including nursing considerations and patient teaching.